Skip to main content
S&P 5007,580.46+0.52%DOW51,764.10-0.42%NASDAQ25,425.58+1.04%BTC$77,609.00+0.67%ETH$2,295.24+1.76%GOLD$3,939.80-0.75%OIL$95.92-0.56%
Smart Investors Daily
SID Premium
Lexicon Pharmaceuticals, Inc. logo

NASDAQ · LXRX

Lexicon Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.44

Up+$0.03 (+1.74%)

Updated Nov 3, 2026, 5:19 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
481.5M
P/E ratio
-3.99
Dividend yield
0.00%
52-week range
$1.37 – $2.68
Volume
2.02M
Avg. volume
2.31M

Price performance · LXRX

LXRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

LXRX closed at $1.44 after 21 trading sessions, down 17.24% for the selected period.

Last close
$1.44
Period change
-17.24%
Period low
$1.42
Period high
$1.76
Daily close
View OHLC price history
LXRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$1.44$1.45$1.40$1.442.02M
Oct 30, 2026$1.47$1.4961$1.375$1.422.44M
Oct 29, 2026$1.50$1.52$1.43$1.481.77M
Oct 28, 2026$1.47$1.49$1.43$1.4851.62M
Oct 27, 2026$1.47$1.49$1.435$1.481.86M
Oct 26, 2026$1.40$1.48$1.40$1.452.21M
Oct 23, 2026$1.50$1.50$1.365$1.422.68M
Oct 22, 2026$1.56$1.59$1.48$1.491.32M
Oct 21, 2026$1.59$1.6171$1.545$1.561.4M
Oct 20, 2026$1.56$1.63$1.545$1.581.41M
Oct 19, 2026$1.55$1.5799$1.5102$1.551.72M
Oct 16, 2026$1.68$1.68$1.52$1.522.01M
Oct 15, 2026$1.63$1.675$1.62$1.651.43M
Oct 14, 2026$1.61$1.63$1.56$1.601.91M
Oct 13, 2026$1.65$1.655$1.59$1.612.05M
Oct 12, 2026$1.65$1.67$1.605$1.652.03M
Oct 9, 2026$1.75$1.77$1.67$1.682.07M
Oct 8, 2026$1.75$1.78$1.695$1.763.32M
Oct 7, 2026$1.73$1.77$1.7137$1.761.1M
Oct 6, 2026$1.75$1.78$1.72$1.751.64M
Oct 5, 2026$1.83$1.83$1.72$1.742.72M

Latest LXRX news

The latest Smart Investors Daily articles mentioning LXRX.

Stock researchCompany · Overview

LXRX research

Overview

Company profile and research snapshot.

Company profile

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
LXRX recent ratings
DateFirmRatingTarget
Sep 28, 2026Cantor FitzgeraldOverweight—
May 11, 2026CitigroupBuy—
Mar 23, 2026HC Wainwright & Co.Buy—
Mar 10, 2026CitigroupBuy—
Mar 5, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry – -- Substantial over enrollment strengthens statistical power and provides robust dataset to evaluate the efficacy and safety of sotagliflozin -- THE WOODLANDS, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical compa

Benzinga · Oct 23, 2026

Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing pivotal Phase 3

Yahoo · Oct 21, 2026

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotagliflozin on platelet activity and thrombus formation -- -- Findings underscore differentiated biology associated with dual SGLT1 and SGLT 2 inhibition -- THE WOODLANDS, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical com

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By